AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Iridex Corp
XNAS · usd
SIC 3845 · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
FIGI BBG001S7J0Y3
0.75▼ 0.02 (-2.18%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
0.76
Day's Range
0.73 – 0.77
52-Week Range
0.61 – 1.65
Volume
19.0K
Avg Volume
520.9K
Share Statistics
Shares Outstanding
Employees
108
Exchange
XNAS
Listed
1996-02-16
Share count as of August 13, 2026

Iridex Corp (IRIX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Iridex Corp (IRIX)
What is Iridex Corp's Market Cap?
Iridex Corp's Market Cap is $13.1M, based on as-reported figures from SEC (XBRL) filings.
What is Iridex Corp's Price / Sales?
Iridex Corp's Price / Sales is 0.3×, based on as-reported figures from SEC (XBRL) filings.
What is Iridex Corp's Revenue (TTM)?
Iridex Corp's Revenue (TTM) is $51.6M, based on as-reported figures from SEC (XBRL) filings.
What is Iridex Corp's Net Income (TTM)?
Iridex Corp's Net Income (TTM) is -$3.5M, based on as-reported figures from SEC (XBRL) filings.
What is Iridex Corp's EBITDA?
Iridex Corp's EBITDA is -$2.3M, based on as-reported figures from SEC (XBRL) filings.
What is Iridex Corp's Diluted EPS (TTM)?
Iridex Corp's Diluted EPS (TTM) is -0.20, based on as-reported figures from SEC (XBRL) filings.
What is Iridex Corp's EBITDA Margin?
Iridex Corp's EBITDA Margin is -4.5%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · IRIXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJul 4, 2026Apr 4, 2026Jan 3, 2026Sep 27, 2025Jun 28, 2025Mar 29, 2025Dec 28, 2024Sep 28, 2024Jun 29, 2024Mar 30, 2024Dec 30, 2023Sep 30, 2023Jul 1, 2023Apr 1, 2023Dec 31, 2022Oct 1, 2022
Total revenues
YoY growth-7.4%-0.8%+16.0%+7.8%
Cost of revenues
Gross profit
% of revenue34.2%40.2%37.2%32.1%
Operating expenses:
Research and development
Sales and marketing
General and administrative
Total operating expenses
% of revenue42.4%42.9%37.3%43.4%
Loss from operations
% of revenue-8.2%-2.7%-0.1%-11.3%
Other expense, net
Loss from operations before provision for income taxes
Provision for income taxes
Net loss
% of revenue-10.1%-4.4%-1.2%-12.6%
Basic
Diluted